[Epidemiological and economic aspects of chelating therapy in the therapeutic center of thalassemia in Morocco].
The study aims to give a general idea about the new experience of chelating drugs among beta-thalassemia patients. It is a declarative survey. It was done in the therapy center of Morocco. Statistics were done in the Laboratory of Biological Essays in Kenitra. All economic and pharmacological data were given by Novartis. Sample size was 89. The only treatment available now in the therapy center is deferiprone. 78% of patients attending the service regularly take deferiprone as treatment while 13% of them combine deferiprone and deferoxamine. Most of the patients take treatments regularly. Chelators have reduced mortality. Patients taking deferoxamine experienced injection site reactions. Most of ADR due to deferiprone were digestive. In conclusion, the main problem with chelators in Morocco is lack of accessibility to drugs (except for some patients insured or payant).
Agouzal
M
M
Université Ibn Tofaïl, Faculté des Sciences, Laboratoire des Essais Biologiques, Kenitra, Maroc. agouzal.mouna@yahoo.fr
Quyou
A
A
Benchekroune
K
K
Khattab
M
M
D000293:Adolescent; D000328:Adult; D001565:Benzoates / Q000191:economics / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D000077588:Deferasirox; D000077543:Deferiprone; D003676:Deferoxamine / Q000191:economics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007223:Infant; D007502:Iron Chelating Agents / Q000191:economics / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009018:Morocco; D011446:Prospective Studies; D011728:Pyridones / Q000191:economics / Q000627:therapeutic use*; D014230:Triazoles / Q000191:economics / Q000627:therapeutic use*; D055815:Young Adult; D017086:beta-Thalassemia / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology
D001565:Benzoates; D007502:Iron Chelating Agents; D011728:Pyridones; D014230:Triazoles; D000077543:Deferiprone; D003676:Deferoxamine; D000077588:Deferasirox